AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30761846 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein herniorrhaphy (OLR)
Number of subjects: 302
Study 28614399 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS over the left DLPFC for 7 consecutive days
Number of subjects: 25
Study 28614399 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 25
Study 27038611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dader method for pharmaceutical care
Number of subjects: 120
Study 27038611 — intervention group
Group type: COMPARATOR
Intervention: Health/dietary counseling and risk reduction (Control)
Number of subjects: 120
Study 25261605 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oxygen therapy
Number of subjects: 18
Study 25261605 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 18
Study 21842241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination PPI plus rebamipide
Number of subjects: 170
Study 21842241 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 170
Study 19874926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac vaccine (3 doses, 0-1-6 month scheme)
Number of subjects: 28
Study 17257476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen (APAP) 37.5 mg tramadol/325 mg APAP, up to 1-2 tablets four times daily for 66 days
Number of subjects: 313
Study 17257476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 17257476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen (APAP)
Number of subjects: 313
Study 15279347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Number of subjects: 230
Study 15279347 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 230
Study 11262515 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (18 g)
Number of subjects: 12
Study 11262515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9853542 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (betaC) supplementation (30 mg daily)
Number of subjects: 0
Study 9853542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9853542 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (betaC) supplementation with UV exposure
Number of subjects: 0
Study 9853542 — intervention group
Group type: EXPERIMENTAL
Intervention: UV exposure
Number of subjects: 0
Study 7986136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic staging with laparoscopic ultrasonography
Number of subjects: 50
Study 7986136 — intervention group
Group type: COMPARATOR
Intervention: No laparoscopic assessment
Number of subjects: 50
Study 7986136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasonography
Number of subjects: 50
Study 7986136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 50
Study 2646779 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-P
Number of subjects: 224
Study 2646779 — intervention group
Group type: COMPARATOR
Intervention: AZA-P-ALG
Number of subjects: 224
Study 2646779 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple/Quadruple therapy (AZA-P-CsA or AZA-P-CsA-ALG)
Number of subjects: 224
Study 31081924 — intervention group
Group type: EXPERIMENTAL
Intervention: verum CBM/verum tDCS
Number of subjects: 79
Study 31081924 — intervention group
Group type: COMPARATOR
Intervention: verum CBM/sham tDCS
Number of subjects: 79
Study 31081924 — intervention group
Group type: COMPARATOR
Intervention: sham CBM/verum tDCS
Number of subjects: 79
Study 31081924 — intervention group
Group type: COMPARATOR
Intervention: sham CBM/sham tDCS
Number of subjects: 79
Study 31081924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBM and tDCS
Number of subjects: 79
Study 28462519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (7.5 mg b.i.d.)
Number of subjects: 179
Study 28462519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 28462519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 179
Study 26355170 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (5.0 to 8.5 mm)
Number of subjects: 28
Study 26355170 — intervention group
Group type: COMPARATOR
Intervention: Augmented group with longer implants (at least 11.5 mm)
Number of subjects: 28
Study 26355170 — intervention group
Group type: COMPARATOR
Intervention: Augmented group
Number of subjects: 28
Study 26355170 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants and augmented group
Number of subjects: 28
Study 26355170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 23801842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LAM and ADV therapy
Number of subjects: 140
Study 23801842 — intervention group
Group type: COMPARATOR
Intervention: LAM alone (monotherapy)
Number of subjects: 140
Study 20878425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day mesalazine (two divided doses)
Number of subjects: 123
Study 20878425 — intervention group
Group type: COMPARATOR
Intervention: 2.25 g/day mesalazine (three divided doses)
Number of subjects: 123
Study 20878425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day mesalazine
Number of subjects: 123
Study 20878425 — intervention group
Group type: COMPARATOR
Intervention: 2.25 g/day mesalazine
Number of subjects: 123
Study 20026933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic pressure-relief protocol using an individually adjusted automated seat in wheelchairs.
Number of subjects: 44
Study 20026933 — intervention group
Group type: COMPARATOR
Intervention: Standard wheelchair seating (control group).
Number of subjects: 44
Study 17675076 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-based pacing
Number of subjects: 2568
Study 17675076 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2568
Study 17675076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing (irrespective of pacing mode)
Number of subjects: 2568
Study 15543905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed prosthodontics
Number of subjects: 107
Study 15543905 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable dentures
Number of subjects: 107
Study 15543905 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete dentures
Number of subjects: 107
Study 15543905 — intervention group
Group type: COMPARATOR
Intervention: Removable/Complete dentures
Number of subjects: 107
Study 15543905 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 107
Study 12180581 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg/kg added to local anaesthetic mixture (2% lignocaine and hyaluronidase)
Number of subjects: 24
Study 12180581 — intervention group
Group type: COMPARATOR
Intervention: Control group received 7 ml of a mixture of 2% lignocaine and hyaluronidase with 1 ml normal saline
Number of subjects: 24
Study 10638158 — intervention group
Group type: EXPERIMENTAL
Intervention: BAR (mechanical device)
Number of subjects: 45
Study 10638158 — intervention group
Group type: EXPERIMENTAL
Intervention: GIA stapling device
Number of subjects: 45
Study 10638158 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual suture with interrupted stitches double layer (vicryl)
Number of subjects: 45
Study 10638158 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 7741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine 40 mg intravenously
Number of subjects: 15
Study 7741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine 80 mg intravenously
Number of subjects: 15
Study 7741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine 40 mg orally
Number of subjects: 15
Study 7741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine 80 mg orally
Number of subjects: 15
Study 7741773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine (all doses)
Number of subjects: 15
Study 7741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine (lowest oral dose)
Number of subjects: 15
Study 1970370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporin (initial dose 2.5 mg/kg, mean stabilisation dose 3.8 mg/kg)
Number of subjects: 144
Study 6989432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 10
Study 6989432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-pressure pneumatic compression device (IPCD)
Number of subjects: 10
Study 6989432 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 10
Study 6989432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30256671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target <120 mmHg)
Number of subjects: 4298
Study 30256671 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target <140 mmHg)
Number of subjects: 4298
Study 27379963 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 80
Study 27379963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 80
Study 27379963 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional strength training
Number of subjects: 80
Study 27379963 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 24633694 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐occurring internalizing and externalizing comorbidities
Number of subjects: 392
Study 24633694 — intervention group
Group type: COMPARATOR
Intervention: Internalizing comorbidity alone
Number of subjects: 392
Study 24633694 — intervention group
Group type: COMPARATOR
Intervention: Externalizing comorbidity alone
Number of subjects: 392
Study 24633694 — intervention group
Group type: COMPARATOR
Intervention: No comorbidities
Number of subjects: 392
Study 24472614 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 68
Study 24472614 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 68
Study 22625222 — intervention group
Group type: EXPERIMENTAL
Intervention: Krachtvoer programme
Number of subjects: 1875
Study 22625222 — intervention group
Group type: COMPARATOR
Intervention: Regular nutrition lessons (control)
Number of subjects: 1875
Study 19604181 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (n = 92)
Number of subjects: 180
Study 19604181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music, n = 88)
Number of subjects: 180
Study 18087004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone plus azathioprine
Number of subjects: 73
Study 18087004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone plus mycophenolate mofetil
Number of subjects: 73
Study 15497024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (100 mg per capsule, 2 capsules taken 2-3 hours before flight, 2 capsules 6 hours later, 1 capsule the next day)
Number of subjects: 198
Study 15497024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (comparable to Pycnogenol, same intervals)
Number of subjects: 198
Study 11585312 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling
Number of subjects: 400
Study 11585312 — intervention group
Group type: COMPARATOR
Intervention: Primary vitrectomy
Number of subjects: 400
Study 9008444 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step 1 diet plus lovastatin
Number of subjects: 40
Study 9008444 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association Step 1 diet plus placebo
Number of subjects: 40
Study 8342398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen-progesterone therapy (uncontrolled trial)
Number of subjects: 20
Study 8342398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.050 mg ethinyloestradiol and 1 mg norethisterone (double-blind randomized placebo-controlled trial)
Number of subjects: 20
Study 3015184 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 145
Study 3015184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (40 Gy in split-course)
Number of subjects: 145
Study 3015184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 145
Study 31985067 — intervention group
Group type: EXPERIMENTAL
Intervention: myFAMI intervention
Number of subjects: 40
Study 31985067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 31856576 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 392
Study 27915159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 49
Study 27915159 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 49
Study 27915159 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 49
Study 26525615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cytoflavin (2 ml per 1 kg of body weight per day for five days)
Number of subjects: 89
Study 26525615 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 89
Study 23088837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu(®) aScope™ 2
Number of subjects: 50
Study 23088837 — intervention group
Group type: COMPARATOR
Intervention: Conventional fibrescope
Number of subjects: 50
Study 22051427 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements recorded in electronic medical records (EMRs)
Number of subjects: 0
Study 22051427 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure measurements taken at research study visit
Number of subjects: 0
Study 19407274 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100
Study 19407274 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100
Study 19407274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed treatment group
Number of subjects: 100
Study 19407274 — intervention group
Group type: COMPARATOR
Intervention: No-antipsychotic group
Number of subjects: 100
Study 19407274 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 17589948 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC7 (7-day triple therapy: omeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
Number of subjects: 131
Study 17589948 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC14 (14-day triple therapy: omeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
Number of subjects: 131
Study 17589948 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC7 (7-day triple therapy)
Number of subjects: 131
Study 17589948 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC14 (14-day triple therapy)
Number of subjects: 131
Study 15107145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.39 mg THC/day
Number of subjects: 7
Study 15107145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.47 mg THC/day
Number of subjects: 7
Study 15107145 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg THC/day
Number of subjects: 7
Study 15107145 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.8 mg THC/day
Number of subjects: 7
Study 15107145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.39 to 14.8 mg THC/day
Number of subjects: 7
Study 11569764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-generational discount rates for long delays (30-900 years)
Number of subjects: 0
Study 11569764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-generational discount rates for saving lives, improving health, and financial benefits
Number of subjects: 0
Study 11569764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-generational discounting of life-saving programs
Number of subjects: 0
Study 9645714 — intervention group
Group type: EXPERIMENTAL
Intervention: Preenucleation radiation treatment
Number of subjects: 1527
Study 9645714 — intervention group
Group type: COMPARATOR
Intervention: Uveal melanoma
Number of subjects: 1527
Study 9645714 — intervention group
Group type: COMPARATOR
Intervention: Increased pigmentation
Number of subjects: 1527
Study 9645714 — intervention group
Group type: COMPARATOR
Intervention: Increased necrosis
Number of subjects: 1527
Study 7961018 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy (CG)
Number of subjects: 1446
Study 7961018 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiotherapy (SG)
Number of subjects: 1446
Study 3314526 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1%
Number of subjects: 11
Study 3314526 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxycytidine 100 microM
Number of subjects: 11
Study 2265802 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatozoa capacitated in hyperosmotic medium of 315 mosm/kg
Number of subjects: 54
Study 2265802 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatozoa capacitated in hyperosmotic medium of 345 mosm/kg
Number of subjects: 54
Study 2265802 — intervention group
Group type: COMPARATOR
Intervention: Spermatozoa incubated in medium of 285 mosm/kg
Number of subjects: 54
Study 989400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of diazepam
Number of subjects: 180
Study 989400 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5653 (three doses)
Number of subjects: 180
Study 989400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 989400 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 180
Study 31311721 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir (2 μmol/kg)
Number of subjects: 24
Study 31311721 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir (5 μmol/kg)
Number of subjects: 24
Study 31311721 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir (10 μmol/kg)
Number of subjects: 24
Study 31311721 — intervention group
Group type: COMPARATOR
Intervention: NAC alone
Number of subjects: 24
Study 31311721 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir
Number of subjects: 24
Study 28003211 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-water immersion (30-min waist-level immersion in 42.1 ± 0.6°C water)
Number of subjects: 21
Study 26069291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg iv/4 weeks, 12 doses)
Number of subjects: 100
Study 23441762 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 80
Study 23441762 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 10 mg
Number of subjects: 80
Study 23441762 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg
Number of subjects: 80
Study 23441762 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 10 mg
Number of subjects: 80
Study 21941011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (wet bags of ice during each inter-set rest interval)
Number of subjects: 16
Study 21941011 — intervention group
Group type: COMPARATOR
Intervention: Control (no ice application)
Number of subjects: 16
Study 19705620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid test detecting heterophil antibodies
Number of subjects: 163
Study 19705620 — intervention group
Group type: COMPARATOR
Intervention: Specific immunoglobulins directed against Epstein‐Barr virus (EBV)
Number of subjects: 163
Study 16735654 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Administration of Medication (SAM) tool
Number of subjects: 56
Study 15558387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha liner with distal locking pin
Number of subjects: 13
Study 15558387 — intervention group
Group type: COMPARATOR
Intervention: Pe‐Lite liner with neoprene suspension sleeve
Number of subjects: 13
Study 11510389 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment based on symptoms
Number of subjects: 349
Study 11510389 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 349
Study 11510389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 349
Study 11510389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt endoscopy
Number of subjects: 349
Study 9265939 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 33
Study 9265939 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 33
Study 9265939 — intervention group
Group type: COMPARATOR
Intervention: Control situation (baseline)
Number of subjects: 33
Study 8333260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1%
Number of subjects: 0
Study 8333260 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropyl methylcellulose 2%
Number of subjects: 0
Study 3088858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.i.d.
Number of subjects: 9
Study 3088858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms hs
Number of subjects: 9
Study 3088858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29082629 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization within 30 days
Number of subjects: 6584
Study 29082629 — intervention group
Group type: EXPERIMENTAL
Intervention: Early readmission (0-7 days)
Number of subjects: 6584
Study 29082629 — intervention group
Group type: EXPERIMENTAL
Intervention: Late readmission (8-30 days)
Number of subjects: 6584
Study 28434760 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) supplementation at a dosage of 1.28 g/day for 12 weeks
Number of subjects: 88
Study 28434760 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (control group) for 12 weeks
Number of subjects: 88
Study 25194450 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous intensity resistance training
Number of subjects: 51
Study 25194450 — intervention group
Group type: COMPARATOR
Intervention: Stretching (placebo control)
Number of subjects: 51